dostarlimab
gsk
['dostarlimab']
study used dostarlimab (anti-pd-1) for a total of 6 months. can we substitute with other agents? #asco22 
Chief MedOnc @SylvesterCancer. Helping improve Cancer Control in LMICs. Editor-in-Chief @JCOGO_ASCO, Board Member @UICC - co-chair #ATOMcoalition